A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
Financial Post ·
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) — Biotech Insider News Commentary – An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and Moderna announced detailed results from the Phase 3 INTerpath-001 trial […]
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. Read More